Frontline treatment with nintedanib plus pemetrexed and cisplatin improved progression-free survival (PFS) by 3.7 months for chemotherapy-naive patients with malignant pleural mesothelioma (MPM), according to data reported at the 2017 ASCO Annual Meeting.
In the phase II trial, known as LUME-Meso, the median PFS was 9.4 months with the nintedanib combination versus 5.7 months with pemetrexed and cisplatin alone (HR, 0.54; 95% CI, 0.33-0.87; P = .010). The median overall survival (OS) was 18.3 months with nintedanib versus 14.2 months with chemotherapy alone; however, this finding was not statistically significant (HR, 0.77; 95% CI, 0.46-1.29; P = .319).
Outcomes with nintedanib seemed more promising for patients with epithelioid MPM, which is the only histology being included in an ongoing phase III study exploring the triplet. In those with epithelioid MPM, the median OS was 20.6 versus 15.2 months; however, this improvement was also not statistically significant (HR, 0.70; 95% CI, 0.40-1.21; P = .197). The median PFS in this population was 9.7 months with nintedanib versus 5.7 months with chemotherapy alone (HR, 0.49; 0.30-0.82; P = .006).
[Article continues at original source]
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.